Rezolute (RZLT) Income from Continuing Operations (2012 - 2026)
Rezolute (RZLT) posted Income from Continuing Operations of 20928000.0 for Q1 2026, up 17.2% sequentially from 25274000.0 in Q4 2025, and up 13.68% YoY from 18409957.62 in Q1 2025.
Powered by 
Analysis
Rezolute (RZLT) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Rezolute has reported Income from Continuing Operations for 15 years, with the latest figure at 20928000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 13.68% year-over-year to 20928000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 163257000.0 (down 43.66% YoY) and the FY2025 annual result came in at 164347000.0, down 105.04% from the prior year.
- Income from Continuing Operations climbed to 20928000.0 in Q1 2026 per RZLT's latest filing, from 25274000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9985000.0 in Q3 2022 and troughed at 92461000.0 in Q3 2025.
- A 5-year average of 23745588.24 and a median of 19843000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 27.66% in 2025, down 158.47% in 2025.
- Over 5 years, Income from Continuing Operations stood at 14141000.0 in 2022, then fell by 0.68% to 14237000.0 in 2023, then tumbled by 145.39% to 34936000.0 in 2024, then climbed by 27.66% to 25274000.0 in 2025, then increased by 17.2% to 20928000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 20928000.0, 25274000.0, and 92461000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rezolute | 475.98 Mn | 475.98 Mn | - | -16.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -16.17 Mn |
| Dec 31, 2025 | -22.77 Mn |
| Sep 30, 2025 | -18.14 Mn |
| Jun 30, 2025 | -24.41 Mn |
| Mar 31, 2025 | -18.91 Mn |
| Dec 31, 2024 | -15.74 Mn |
| Sep 30, 2024 | -15.36 Mn |
| Jun 30, 2024 | -22.06 Mn |
| Mar 31, 2024 | -15.09 Mn |
| Dec 31, 2023 | -13.89 Mn |
| Sep 30, 2023 | -14.51 Mn |
| Jun 30, 2023 | -12.76 Mn |
| Mar 31, 2023 | -15.66 Mn |
| Dec 31, 2022 | -13.54 Mn |
| Sep 30, 2022 | -9.82 Mn |
| Jun 30, 2022 | -11.78 Mn |
| Mar 31, 2022 | -11.20 Mn |
| Dec 31, 2021 | -12.59 Mn |
| Sep 30, 2021 | -8.08 Mn |
| Jun 30, 2021 | -7.07 Mn |